title: Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant.
abstract: Post-transplant lymphoproliferative disorder (PTLD) in the central nervous system (CNS) is a very rare complication of haematopoietic stem cell transplant (HSCT) and has a dismal prognosis. We report the successful treatment of this disorder with intrathecal rituximab therapy in two children who developed isolated CNS PTLD after HSCT. These children had failed to respond to standard chemotherapy, intravenous rituximab and EBV specific cellular therapy.
authors.affiliation: Department of Blood and Marrow Transplant, Royal Manchester Children's Hospital, Central Manchester Foundation Trust, Oxford Road, Manchester, UK.
authors.forename: Denise K
authors.initials: DK
authors.lastname: Bonney
authors.forename: Ei E
authors.initials: EE
authors.lastname: Htwe
authors.forename: Andrew
authors.initials: A
authors.lastname: Turner
authors.forename: Anna
authors.initials: A
authors.lastname: Kelsey
authors.forename: Abdu
authors.initials: A
authors.lastname: Shabani
authors.forename: Stephen
authors.initials: S
authors.lastname: Hughes
authors.forename: Imelda
authors.initials: I
authors.lastname: Hughes
authors.forename: Robert F
authors.initials: RF
authors.lastname: Wynn
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002493:Central Nervous System Diseases / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D002675:Child, Preschool; D020031:Epstein-Barr Virus Infections / Q000188:drug therapy* / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007278:Injections, Spinal; D015448:Leukemia, B-Cell / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D051359:Lymphohistiocytosis, Hemophagocytic / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D008232:Lymphoproliferative Disorders / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D008279:Magnetic Resonance Imaging; D008297:Male; D000069283:Rituximab; D014775:Virus Activation
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab